XML 57 R30.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUE (Tables)
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table summarizes the disaggregation of revenue by nature:
 Year Ended December 31,
Dollars in Millions202220212020
Net product sales$44,671 $45,055 $41,321 
Alliance revenues742 716 615 
Other revenues746 614 582 
Total Revenues$46,159 $46,385 $42,518 
Schedule of Revenue by Major Customers
Gross revenue to the three largest pharmaceutical wholesalers in the U.S. as a percentage of U.S. gross revenues was as follows:
 Year Ended December 31,
 202220212020
McKesson Corporation32 %32 %31 %
AmerisourceBergen Corporation25 %25 %25 %
Cardinal Health, Inc.21 %20 %19 %
Reconciliation of Gross Product Sales to Net Product Sales
The following table summarizes GTN adjustments:
 Year Ended December 31,
Dollars in Millions202220212020
Gross product sales$69,633 $67,897 $60,016 
GTN adjustments(a)
Charge-backs and cash discounts(7,469)(7,253)(5,827)
Medicaid and Medicare rebates(11,362)(9,374)(7,595)
Other rebates, returns, discounts and adjustments(6,131)(6,215)(5,273)
Total GTN adjustments(24,962)(22,842)(18,695)
Net product sales$44,671 $45,055 $41,321 
(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $229 million in 2022, $319 million in 2021 and $106 million in 2020.
Disaggregation of Revenue by Product and Region
The following table summarizes the disaggregation of revenue by product and region:
 Year Ended December 31,
Dollars in Millions202220212020
In-Line Products
Eliquis$11,789 $10,762 $9,168 
Opdivo8,249 7,523 6,992 
Pomalyst/Imnovid3,497 3,332 3,070 
Orencia3,464 3,306 3,157 
Sprycel2,165 2,117 2,140 
Yervoy2,131 2,026 1,682 
Empliciti296 334 381 
Mature and other brands1,749 1,900 2,217 
New Product Portfolio
Reblozyl717 551 274 
Abecma388 164 — 
Opdualag252 — — 
Zeposia250 134 12 
Breyanzi182 87 — 
Onureg124 73 17 
Inrebic85 74 55 
Camzyos24— — 
Sotyktu8— — 
Recent LOE Products(a)
Revlimid9,978 12,821 12,106 
Abraxane811 1,181 1,247 
Total Revenues$46,159 $46,385 $42,518 
United States$31,828 $29,214 $26,577 
International13,497 16,319 15,310 
Other(b)
834 852 631 
Total Revenues$46,159 $46,385 $42,518 
(a)    Recent LOE Products include products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity.
(b)    Other include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.